Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics

다국어 초록 (Multilingual Abstract)

Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver diseases worldwide and its incidence continues to increase. NAFLD occurs when the body can no longer effectively store excess energy in the adipose tissue. Despite the increasing prevalence of NAFLD, making lifestyle changes, including increased exercise, is often an elusive goal for patients with NAFLD. The liver directly connects to the gut-gastrointestinal milieu via the portal vein, which are all part of the gut-liver axis. Therefore, the gut-microbiome and microbial products have been actively studied as likely key factors in NAFLD pathophysiology. Hence, dysbiosis of the gut microbiome and therapeutic manipulation of the gut-liver axis are being investigated. Novel therapeutic approaches for modulating gut microbiota through the administration of probiotics, prebiotics, synbiotics, and antibiotics have been proposed with numerous promising initial reports on the effectiveness and clinical applications of these approaches. This review delves into the current evidence on novel therapies that modulate gut microbiota and discusses ongoing clinical trials targeting the gut-liver axis for the management and prevention of NAFLD.

참고문헌 (Reference)

1 Mencarelli, A., "VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation" 7 : e45425-, 2012

2 Vrieze, A., "Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome" 143 : 913-916, 2012

3 Boursier, J., "The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota" 63 : 764-775, 2016

4 Jirillo, E., "The role of the liver in the response to LPS: Experimental and clinical findings" 8 : 319-327, 2002

5 Ponziani, F. R., "The role of antibiotics in gut microbiota modulation:The eubiotic effects of Rifaximin" 34 : 269-278, 2016

6 Llorente, C., "The gut microbiota and liver disease" 1 : 275-284, 2015

7 Rinella, M., "The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health" 64 : 19-22, 2016

8 Russell, D.W., "The enzymes, regulation, and genetics of bile acid synthesis" 72 : 137-174, 2003

9 McCullough, A. J, "The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease" 8 : 521-533, 2004

10 Verbeke, L., "The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats" 185 : 409-419, 2015

11 Wiest, R., "Targeting the gut-liver axis in liver disease" 67 : 1084-1103, 2017

12 Thomas, C., "Targeting bile-acid signalling for metabolic diseases" 7 : 678-693, 2008

13 Wieland, A., "Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease" 42 : 1051-1063, 2015

14 Tarantino, G., "Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease" 10 : 889-902, 2015

15 Eslamparast, T., "Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study" 99 : 535-542, 2014

16 Mofidi, F., "Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial" 117 : 662-668, 2017

17 Farhadi, A., "Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in non-alcoholic steatohepatitis" 28 : 1026-1033, 2008

18 Rayes, N., "Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation–a randomized, double-blind trial" 5 : 125-130, 2005

19 Xu, R. Y., "Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model" 50 : 72-77, 2012

20 Wu, W. C., "Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats" 14 : 313-317, 2008

21 Sanyal, A. J., "Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C" 43 : 682-689, 2006

22 Bilzer, M., "Role of Kupffer cells in host defense and liver disease" 26 : 1175-1186, 2006

23 Bajaj, J. S., "Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy" 140 : 478-487, 2011

24 Woodhouse, C. A., "Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease" 47 : 192-202, 2018

25 Alisi, A., "Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis" 39 : 1276-1285, 2014

26 Bajaj, J. S., "Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis" 39 : 1113-1125, 2014

27 Esposito, E., "Probiotics reduce the inflammatory response induced by a highfat diet in the liver of young rats" 139 : 905-911, 2009

28 Xue, L., "Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia" 7 : 45176-, 2017

29 Ma, X., "Probiotics improve high fat dietinduced hepatic steatosis and insulin resistance by increasing hepatic NKT cells" 49 : 821-830, 2008

30 De Santis, A., "Probiotics for the hemodynamic alterations of patients with liver cirrhosis" 95 : 323-324, 2000

31 Pereg, D., "Probiotics for patients with compensated liver cirrhosis: A double-blind placebo-controlled study" 27 : 177-181, 2011

32 Li, Z., "Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease" 37 : 343-350, 2003

33 Hutkins, R. W., "Prebiotics: Why definitions matter" 37 : 1-7, 2016

34 Roberfroid, M., "Prebiotic effects: Metabolic and health benefits" 104 (104): S1-S63, 2010

35 Sanyal, A. J., "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis" 362 : 1675-1685, 2010

36 Eguchi, S., "Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: A prospective randomized study" 201 : 498-502, 2011

37 Mazzotti, A., "Pathophysiology of nonalcoholic fatty liver disease:Lifestyle-gut-gene interaction" 34 (34): 3-10, 2016

38 Kundu, P., "Our gut microbiome: The evolving inner self" 171 : 1481-1493, 2017

39 Nair, S., "Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis" 96 : 1200-1204, 2001

40 Carr, R. M., "Nonalcoholic fatty liver disease: Pathophysiology and management" 45 : 639-652, 2016

41 Rinella, M. E, "Nonalcoholic fatty liver disease: A systematic review" 313 : 2263-2273, 2015

42 Seto, W.K., "Nonalcoholic fatty liver disease in Asia: Emerging perspectives" 52 : 164-174, 2017

43 Chavez-Tapia, N. N., "New insights into the pathophysiology of nonalcoholic fatty liver disease" 8 (8): S9-S17, 2009

44 Wong, V. W., "Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study" 8 : e62885-, 2013

45 Chassaing, B., "Microbiota-liver axis in hepatic disease" 59 : 328-339, 2014

46 Anne-Marie Cassard, "Microbiota, a key player in alcoholic liver disease" 대한간학회 24 (24): 100-107, 2018

47 Loft, S., "Metronidazole pharmacokinetics in patients with hepatic encephalopathy" 22 : 117-123, 1987

48 Cui, X., "Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients" 8 : 635-, 2018

49 Dumas, M. E., "Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice" 103 : 12511-12516, 2006

50 Jernberg, C., "Longterm ecological impacts of antibiotic administration on the human intestinal microbiota" 1 : 56-66, 2007

51 Ruiz, A. G., "Lipopolysaccharide-binding protein plasma levels and liver TNFalpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis" 17 : 1374-1380, 2007

52 Bajaj, J. S., "Linkage of gut microbiome with cognition in hepatic encephalopathy" 302 : G168-G175, 2012

53 Ritze, Y., "Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice" 9 : e80169-, 2014

54 Okubo, H., "Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am. J. Physiol. Gastrointest" 305 : G911-G918, 2013

55 Mouzaki, M., "Intestinal microbiota in patients with nonalcoholic fatty liver disease" 58 : 120-127, 2013

56 Jiang, C., "Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease" 125 : 386-402, 2015

57 Wahlstrom, A., "Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism" 24 : 41-50, 2016

58 Schnabl, B., "Interactions between the intestinal microbiome and liver diseases" 146 : 1513-1524, 2014

59 Miele, L., "Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease" 49 : 1877-1887, 2009

60 Cope, K., "Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis" 119 : 1340-1347, 2000

61 Abdelmalek, M. F., "Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease" 51 : 1961-1971, 2010

62 Boursier, J., "Implication of gut microbiota in nonalcoholic fatty liver disease" 11 : e1004559-, 2015

63 Ding, S., "High-fat diet: Bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse" 5 : e12191-, 2010

64 Garcia-Martinez, I., "Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9" 126 : 859-864, 2016

65 Etienne-Mesmin, L., "Hepatocyte Toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease" 2 : 584-604, 2016

66 Compare, D., "Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease" 22 : 471-476, 2012

67 Loguercio, C., "Gut-liver axis: A new point of attack to treat chronic liver damage?" 97 : 2144-2146, 2002

68 Brandl, K., "Gut-liver axis at the frontier of host-microbial interactions" 312 : G413-G419, 2017

69 Miele, L., "Gut-liver axis and microbiota in NAFLD:Insight pathophysiology for novel therapeutic target" 19 : 5314-5324, 2013

70 Bindels, L. B., "Gut microbiota-derived propionate reduces cancer cell proliferation in the liver" 107 : 1337-1344, 2012

71 Sayin, S. I., "Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist" 17 : 225-235, 2013

72 Del Chierico, F., "Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaomics-based approach" 65 : 451-464, 2017

73 Zhu, L., "Gut microbiota produce alcohol and contribute to NAFLD" 65 : 1232-, 2016

74 Lambert, J. E., "Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: A randomized controlled trial protocol" 15 : 169-, 2015

75 Larsen, N., "Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults" 5 : e9085-, 2010

76 Zhao, Y., "Gut microbiota composition modifies fecal metabolic profiles in mice" 12 : 2987-2999, 2013

77 Wang, Z., "Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease" 472 : 57-63, 2011

78 Lonardo, A., "Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes" 64 : 1388-1389, 2016

79 Sookoian, S., "Genetic predisposition in nonalcoholic fatty liver disease" 23 : 1-12, 2017

80 Jones, B. V., "Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome" 105 : 13580-13585, 2008

81 Gupta, A., "Fecal microbiota transplantation" 318 : 102-, 2017

82 Vindigni, S.M., "Fecal microbiota transplantation" 46 : 171-185, 2017

83 Raman, M., "Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease" 11 : 868-875, 2013

84 Pineiro, M., "FAO technical meeting on prebiotics" 42 (42): S156-S159, 2008

85 Gibson, G. R., "Expert consensus document: The international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics" 14 : 491-502, 2017

86 Gangarapu, V., "Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease" 27 : 840-845, 2015

87 Famouri, F., "Effects of probiotics on non-alcoholic fatty liver disease in obese children and adolescents: A randomized clinical trial" 64 : 413-417, 2017

88 Saez-Lara, M. J., "Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials" 17 : 928-, 2016

89 Delzenne, N.M., "Effects of fructans-type prebiotics on lipid metabolism" 73 : 456S-458S, 2001

90 Raso, G. M., "Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and Toll-like receptor expression in rats fed a high-fat diet" 25 : 81-90, 2014

91 Vajro, P., "Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease" 52 : 740-743, 2011

92 Mykhal’chyshyn, H. P., "Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease" 2 : 56-62, 2013

93 Soh, S. E., "Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant hepatitis B vaccination" 28 : 2577-2579, 2010

94 Aller, R., "Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial" 15 : 1090-1095, 2011

95 Shavakhi, A., "Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: A double blind randomized clinical trial" 4 : 531-537, 2013

96 Sanchez, M., "Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women" 111 : 1507-1519, 2014

97 Jiang, W., "Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease" 5 : 8096-, 2015

98 Bajaj, J.S., "Drug therapy: Rifaximin" 52 : 1484-1488, 2010

99 Strauss, E., "Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy" 39 : 542-545, 1992

100 Xie, G., "Distinctly altered gut microbiota in the progression of liver disease" 7 : 19355-19366, 2016

101 Pendyala, S., "Diet-induced weight loss reduces colorectal inflammation: Implications for colorectal carcinogenesis" 93 : 234-242, 2011

102 Bajaj, J. S., "Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort" 68 : 234-247, 2018

103 Csak, T., "Deficiency in myeloid differentiation factor-2 and Toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice" 300 : G433-G441, 2011

104 Mas, A., "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial" 38 : 51-58, 2003

105 Nagata, K., "Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis" 32 : 453-468, 2007

106 Zhu, L., "Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients : A connection between endogenous alcohol and NASH" 57 : 601-609, 2013

107 Chen, Y., "Characterization of fecal microbial communities in patients with liver cirrhosis" 54 : 562-572, 2011

108 Pokusaeva, K., "Carbohydrate metabolism in Bifidobacteria" 6 : 285-306, 2011

109 Ridlon, J. M., "Bile salt biotransformations by human intestinal bacteria" 47 : 241-259, 2006

110 Aranha, M. M., "Bile acid levels are increased in the liver of patients with steatohepatitis" 20 : 519-525, 2008

111 Malaguarnera, M., "Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis" 57 : 545-553, 2012

112 Bergheim, I., "Antibiotics protect against fructose-induced hepatic lipid accumulation in mice:Role of endotoxin" 48 : 983-992, 2008

113 Gonzalez, F. J., "An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease" 151 : 845-859, 2016

114 Wang, B., "Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease" 6 : 32002-, 2016

115 Lindheim, L., "Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study" 12 : e0168390-, 2017

116 Suk, K. T., "Alcoholic liver disease:Treatment" 20 : 12934-12944, 2014

117 Lv, L. X., "Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 improves acute liver injury induced by D-galactosamine in rats" 98 : 5619-5632, 2014

118 Letexier, D., "Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans" 77 : 559-564, 2003

119 Turnbaugh, P. J., "A core gut microbiome in obese and lean twins" 457 : 480-484, 2009

120 Hossain, N., "A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD" 2016 : 7109270-, 2016